A Nature Biotechnology study reported an engineered UGA suppressor tRNA designed for in vivo use with AAV vectors to restore protein expression across premature stop codons, offering a potentially disease‑agnostic platform for genetic disorders caused by nonsense mutations. The team optimized tRNA features for delivery and expression in mammalian tissues, showing functional readthrough and therapeutic protein production in preclinical models. Suppressor tRNAs can bypass premature termination codons to produce full‑length proteins; this approach may complement or provide an alternative to gene‑replacement strategies when vector payload or immune considerations limit options.